Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TCbHP in stage II–III HER2-positive breast cancer
ChiCTR2100041951Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Jan 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of docetaxel, carboplatin, pertuzumab and trastuzumab in breast cancer, sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Pathological complete response rate (pCR). Started Jan 2021; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100041951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041951.